Literature DB >> 20345619

Misdiagnosed chronic pelvic pain: pudendal neuralgia responding to a novel use of palmitoylethanolamide.

Rocco Salvatore Calabrò1, Giuseppe Gervasi, Silvia Marino, Pasquale Natale Mondo, Placido Bramanti.   

Abstract

BACKGROUND: Pudendal neuralgia is a cause of chronic, disabling, and often intractable perineal pain presenting as burning, tearing, sharp shooting, foreign body sensation, and it is often associated with multiple, perplexing functional symptoms. CASE REPORT: We report a case of a 40-year-old man presenting with chronic pelvic pain due to pudendal nerve entrapment and successfully treated with palmitoylethanolamide (PEA).
CONCLUSION: PEA may induce relief of neuropathic pain through an action upon receptors located on the nociceptive pathway as well as a more direct action on mast cells via an ALIA (autocoid local injury antagonism) mechanism. As recently demonstrated in animal models, the present case suggests that PEA could be a valuable pharmacological alternative to the most common drugs (anti-epileptics and antidepressants) used in the treatment of neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20345619     DOI: 10.1111/j.1526-4637.2010.00823.x

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  14 in total

Review 1.  Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain.

Authors:  Stephen D Skaper; Laura Facci; Mariella Fusco; Maria Federica Della Valle; Morena Zusso; Barbara Costa; Pietro Giusti
Journal:  Inflammopharmacology       Date:  2013-11-01       Impact factor: 4.473

2.  3T magnetic resonance neurography of pudendal nerve with cadaveric dissection correlation.

Authors:  Avneesh Chhabra; Courtney A McKenna; Vibhor Wadhwa; Gaurav K Thawait; John A Carrino; Gary P Lees; A Lee Dellon
Journal:  World J Radiol       Date:  2016-07-28

Review 3.  Pelvic floor therapies in chronic pelvic pain syndrome.

Authors:  Ragi Doggweiler; Adam F Stewart
Journal:  Curr Urol Rep       Date:  2011-08       Impact factor: 3.092

4.  Pudendal Neuralgia: The Need for a Holistic Approach-Lessons From a Case Report.

Authors:  Simon Gabriël Beerten; Rocco Salvatore Calabrò
Journal:  Innov Clin Neurosci       Date:  2021 Apr-Jun

5.  Intracisternal injection of palmitoylethanolamide inhibits the peripheral nociceptive evoked responses of dorsal horn wide dynamic range neurons.

Authors:  Abimael González-Hernández; Guadalupe Martínez-Lorenzana; Javier Rodríguez-Jiménez; Gerardo Rojas-Piloni; Miguel Condés-Lara
Journal:  J Neural Transm (Vienna)       Date:  2014-06-12       Impact factor: 3.575

6.  Efficacy of ultramicronized palmitoylethanolamide in burning mouth syndrome-affected patients: a preliminary randomized double-blind controlled trial.

Authors:  Giulia Ottaviani; Katia Rupel; Margherita Gobbo; Augusto Poropat; Valentina Zoi; Michela Faraon; Roberto Di Lenarda; Matteo Biasotto
Journal:  Clin Oral Investig       Date:  2018-10-25       Impact factor: 3.573

7.  Potential analgesic effects of a novel N-acylethanolamine acid amidase inhibitor F96 through PPAR-α.

Authors:  Longhe Yang; Long Li; Ling Chen; Yanting Li; Huixia Chen; Yuhang Li; Guangnian Ji; Donghai Lin; Zuguo Liu; Yan Qiu
Journal:  Sci Rep       Date:  2015-08-27       Impact factor: 4.379

8.  Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients.

Authors:  Chiara Schifilliti; Lelio Cucinotta; Viviana Fedele; Carmela Ingegnosi; Salvatore Luca; Carmelo Leotta
Journal:  Pain Res Treat       Date:  2014-04-02

9.  Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain.

Authors:  Dario Cocito; Erdita Peci; Palma Ciaramitaro; Aristide Merola; Leonardo Lopiano
Journal:  Pain Res Treat       Date:  2014-05-20

Review 10.  Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy.

Authors:  Linda Gabrielsson; Sofia Mattsson; Christopher J Fowler
Journal:  Br J Clin Pharmacol       Date:  2016-06-29       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.